FY2025 EPS Estimates for Scholar Rock Lowered by Analyst

Key Points

• Analysts at HC Wainwright have cut their FY2025 earnings per share estimate for Scholar Rock to ($3.66), down from the previous estimate of ($3.63), while maintaining a "Buy" rating with a price target of $44.00.
• The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share, and analysts have provided a range of earnings estimates for subsequent fiscal years.
• Scholar Rock's stock has experienced significant growth potential, as indicated by various research firms giving ratings from "Outperform" to "Strong Buy," with an average price target of $46.40.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Equities researchers at HC Wainwright cut their FY2025 EPS estimates for shares of Scholar Rock in a report released on Tuesday, September 23rd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($3.66) for the year, down from their previous estimate of ($3.63). HC Wainwright has a "Buy" rating and a $44.00 price target on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock's Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($3.51) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.13) EPS and FY2029 earnings at ($0.18) EPS.

Several other research firms also recently commented on SRRK. Leerink Partners began coverage on shares of Scholar Rock in a research note on Monday, September 15th. They issued an "outperform" rating and a $51.00 price target for the company. Cantor Fitzgerald began coverage on shares of Scholar Rock in a research report on Thursday, July 17th. They set an "overweight" rating for the company. Raymond James Financial set a $53.00 price objective on shares of Scholar Rock and gave the stock a "strong-buy" rating in a research report on Wednesday, July 30th. Wedbush reaffirmed an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, June 18th. Finally, Barclays decreased their price objective on shares of Scholar Rock from $45.00 to $44.00 and set an "overweight" rating for the company in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating and ten have given a Buy rating to the company's stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of "Buy" and a consensus target price of $46.40.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $33.72 on Thursday. The company has a fifty day simple moving average of $34.33 and a two-hundred day simple moving average of $33.06. The company has a market cap of $3.24 billion, a price-to-earnings ratio of -11.59 and a beta of 0.36. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.21. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same period last year, the business posted ($0.60) EPS.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Scholar Rock by 2.1% in the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company's stock valued at $155,773,000 after acquiring an additional 101,723 shares during the last quarter. Bellevue Group AG raised its holdings in shares of Scholar Rock by 17.6% in the second quarter. Bellevue Group AG now owns 2,947,295 shares of the company's stock valued at $104,393,000 after buying an additional 440,405 shares during the last quarter. Eventide Asset Management LLC raised its holdings in shares of Scholar Rock by 9.5% in the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company's stock valued at $103,192,000 after buying an additional 251,638 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Scholar Rock by 26.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,018,000 shares of the company's stock valued at $64,879,000 after buying an additional 423,131 shares during the last quarter. Finally, Hood River Capital Management LLC raised its holdings in shares of Scholar Rock by 1.6% in the second quarter. Hood River Capital Management LLC now owns 1,974,964 shares of the company's stock valued at $69,953,000 after buying an additional 30,806 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total value of $32,725.18. Following the completion of the sale, the director directly owned 33,914 shares of the company's stock, valued at $1,103,222.42. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mo Qatanani sold 3,353 shares of the business's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $30.67, for a total transaction of $102,836.51. Following the completion of the sale, the insider directly owned 108,964 shares of the company's stock, valued at approximately $3,341,925.88. This trade represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,739 shares of company stock valued at $1,516,584 over the last ninety days. Insiders own 13.30% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.